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ABSTRACT
Objective: The Korean Society of Lipid and Atherosclerosis (KSoLA) has published 
the Dyslipidemia Fact Sheets in Korea 2020 to provide an overview of magnitude and 
management status of dyslipidemia and their recent trends therein.
Methods: The Fact Sheets were based on the analyses of Korean adults aged 20 years or older 
of the 2007–2018 Korea National Health and Nutrition Examination Survey (KNHANES) and 
the 2002–2018 National Health Insurance Big Data (NHI-BD).
Results: Between 2007 and 2018, the crude prevalence of hypercholesterolemia increased 
from 9.0% to 20.7%. During the same period, its management rate also improved yet 
remained unsatisfactory. In 2018, the prevalence of dyslipidemia was 45.6% in men and 
31.3% in women, which increased with older age and presence of metabolic abnormalities. 
Indeed, the number of people diagnosed with dyslipidemia has increased nearly 8-fold 
from 1.5 million in 2002 to 11.6 million in 2018; alongside, the number of people receiving 
pharmacological treatment for dyslipidemia has also risen. Of the 7.7 million people treated 
for dyslipidemia in 2018, statin accounted for the majority (91.8%) of lipid-lowering drug 
prescriptions, followed by ezetimibe (14.6%), fibrate (8.5%), and omega-3 acid (5.9%). The 
most frequently used combination therapy was statin plus ezetimibe, accounting for 72% of 
dual therapy prescriptions.
Conclusion: Dyslipidemia continues to impose a substantial disease burden in Korea. Both 
healthcare practitioners and patients need to actively adopt guideline-recommended lifestyle 
modification and pharmacological treatment for comprehensive, timely, and sustained 
management.
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INTRODUCTION
Despite substantial improvements in cardiovascular disease (CVD) management and 
outcomes in recent decades, CVD remains the leading cause of mortality globally1 and in 
Korea.2 With rapid population aging, CVD accounts for substantial per-patient healthcare 
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costs and a considerable macroeconomic burden.3 Moreover, the healthy life-year and 
quality-adjusted life-year losses attributable to CVD are projected to exponentially rise 
by 2025.4 Nonetheless, a considerable proportion of this burden can be reduced through 
interventions targeting major CVD precursors, including hypertension, diabetes mellitus, 
and dyslipidemia.5
To promote the comprehensive prevention and treatment of dyslipidemia, the Korean Society 
of Lipid and Atherosclerosis (KSoLA) has recently published the Dyslipidemia Fact Sheets in 
Korea 2020, which present up-to-date information on the epidemiology and management 
status of dyslipidemia based on nationally representative datasets. In this edition, we 
extended the analyses to adults aged 20 years or above to underscore the importance of 
primordial prevention.6 We firmly believe that these fact sheets can increase the public 




The Dyslipidemia Fact Sheets in Korea 2020 analyzed 2 nationally representative datasets: 
the Korea National Health and Nutrition Examination Survey (KNHANES) and the National 
Health Insurance Big Data (NHI-BD). The KNHANES is an ongoing, nationwide surveillance 
system administered by the Korea Centers for Disease Control and Prevention that assesses 
health status and the distribution of chronic disease risk factors. It collects detailed 
information on demographics, disease status, lifestyle, anthropometric characteristics, and 
biochemical measurements from on-site health examinations.7 We analyzed adults aged 
20 years or older with lipid measurements and information on physician diagnosis and 
treatment for dyslipidemia between 2007 and 2018. The National Health Insurance Service 
(NHIS) is the single provider of universal healthcare coverage in Korea. The NHI-BD contains 
sociodemographic information and health insurance claims data of the entire Korean 
population.8 We analyzed adults aged 20 years or older with insurance claims for dyslipidemia 
between 2002 and 2018. The study protocol was approved by the Institutional Review Board 
of Yonsei University Health System, Seoul, Korea (approval 4-2020-0207). The requirement 
for informed consent was waived, because this was a retrospective study of de-identified, 
routinely collected data.
2.  Definitions of hypercholesterolemia and dyslipidemia: based on the 
KNHANES
Hypercholesterolemia was defined as a total cholesterol level ≥240 mg/dL or taking a 
lipid-lowering drug.9 Both crude and age-standardized prevalence were reported. Direct 
standardization was performed based on the 2005 Korean population structure provided 
by the Population and Housing Census, Statistics Korea. The awareness rate was defined as 
the proportion of people who self-reported a physician diagnosis of hypercholesterolemia 
among all people with hypercholesterolemia. The treatment rate was defined as the 
proportion of people taking lipid-lowering drugs ≥20 days per month among all people 
with hypercholesterolemia. Separate control rates were calculated for having total 
cholesterol <200 mg/dL among (1) all people with hypercholesterolemia and (2) people 
pharmacologically treated for hypercholesterolemia.
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Hyper-low-density lipoprotein (LDL)-cholesterolemia was defined as a serum LDL-
cholesterol level ≥160 mg/dL or taking a lipid-lowering drug. Hypo-high-density lipoprotein 
(HDL)-cholesterolemia was defined as a serum HDL-cholesterol level <40 mg/dL. 
Hypertriglyceridemia was defined as a serum triglyceride level ≥200 mg/dL. Dyslipidemia was 
then defined as satisfying one of the definitions stated above.9
3. Healthcare utilization for dyslipidemia: based on the NHI-BD
The diagnosis of dyslipidemia was defined as ≥1 health insurance claim with the International 
Classification of Diseases, 10th revision code E78 each year. Treatment was defined as ≥1 
health insurance claim for a dyslipidemia diagnosis and a lipid-lowering drug prescription 
each year. Adherence to treatment was defined as being prescribed lipid-lowering drugs ≥290 
days (80%) each year. Lipid-lowering drugs were classified as (1) statins, (2) ezetimibe, (3) 
fibrate, (4) omega-3 acid, or (5) others, including niacin or cholestyramine. If the regimen of 
lipid-lowering drugs had been switched, the one with the longest duration in the given year 
was selected as the representative regimen.
RESULTS
1. Prevalence and management of hypercholesterolemia
In 2018, the mean serum total cholesterol levels in adults aged 20 years or older were 192 mg/
dL in men and 194 mg/dL in women (Supplementary Data 1, page 13). Between 2007 and 2018, 
the crude prevalence of hypercholesterolemia increased from 9.0% to 20.7% (Fig. 1A). The 
increase was particularly pronounced in the most recent 5 years, as the prevalence increased 
from 14.3% to 22.4% in men and from 12.0% to 19.0% in women. This increasing trend 
persisted after age-standardization (Supplementary Data 1, page 5). The rising prevalence 
was accompanied by an improvement in management status (Supplementary Data 1, pages 
8-11). However, even in 2016–2018, only 57.6% of adults with hyperlipidemia were aware of 
their disease status and fewer than half (48.1%) received pharmacological treatment (Fig. 1B). 
Consequently, only 41.3% of all adults with hypercholesterolemia achieved a total cholesterol 
level <200 mg/dL (i.e., controlled). However, among adults undergoing treatment, 84.1% had 
controlled total cholesterol levels. Despite higher awareness and treatment rates in women, the 
control rate among those who were treated was higher in men.
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Fig. 1. Prevalence and management of hypercholesterolemia in Korean adults. 
(A) Crude prevalence of hypercholesterolemia in Korean adults, 2007–2018. (B) Management status of hypercholesterolemia in Korean adults, 2016–2018.
2. Prevalence of dyslipidemia
Overall, the prevalence of dyslipidemia was 45.6% in men and 31.3% in women 
(Supplementary Data 1, page 14), and increased with age (Fig. 2A). The prevalence was higher 
in men before the age of 60 years, whereafter the sex trend reversed (Fig. 2B). The prevalence 
of dyslipidemia was also higher among people with metabolic abnormalities; nearly 
70% of people with diabetes and 60% of people with hypertension also had dyslipidemia 
(Supplementary Data 1, pages 22-24).
Based on the analyses of each lipid component, 19.2% of Korean adults had hyper-LDL-
cholesterolemia, 16.1% had hypertriglyceridemia, and 17.7% had hypo-HDL-cholesterolemia 
(Supplementary Data 1, pages 16-21). Notably, 25.7% of men and 43.7% of women aged 60 
years or older had hyper-LDL-cholesterolemia. A large sex difference in hypertriglyceridemia 
was observed among adults 40–49 years, in whom the prevalence was nearly 4 times higher 
in men (32.0%) than in women (7.9%).
3. Treatment for dyslipidemia
The number of people diagnosed with dyslipidemia increased nearly 8-fold from 1.5 
million in 2002 to 11.6 million in 2018 (Fig. 3A). Naturally, the number of people receiving 
pharmacological treatment for dyslipidemia also rose to 7.7 million in 2018. Nearly 75% were 
simultaneously treated for hypertension, diabetes, or both (Supplementary Data 1, pages 28-
29). However, only 4.6 million people were adherent to treatment, comprising approximately 
40% of all patients with dyslipidemia.
Of the 7.7 million people treated for dyslipidemia in 2018, statins accounted for the majority 
of lipid-lowering drug prescriptions (Fig. 3B). In fact, 7.1 million people received statins, 
which accounted for 91.8% of total lipid-lowering prescriptions, followed by ezetimibe 
(14.6%), fibrate (8.5%), and omega-3 acid (5.9%). The use of dual therapy for dyslipidemia 
steadily increased to 18.6% in 2018 (Supplementary Data 1, pages 32-33). The most 
frequently used combination therapy was a statin plus ezetimibe, which accounting for 72% 
of dual therapy prescriptions (Supplementary Data 1, pages 36-37).
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Fig. 2. Prevalence of dyslipidemia in Korean adults. 
(A) Prevalence of dyslipidemia in Korean adults by age, 2016–2018 (p for trend: <0.0001). (B) Prevalence of dyslipidemia in Korean adults by sex and age, 
2016–2018 (p for trend in men: <0.0001 and p for trend in women: <0.0001, respectively).
DISCUSSION
The Dyslipidemia Fact Sheets in Korea 2020 deliver an overview of the magnitude and management 
status of dyslipidemia in Korean adults aged 20 years or older. Overall, we observed a steady 
increase in dyslipidemia prevalence and dyslipidemia-related healthcare use. Simultaneously, the 
management status has also improved, but there remains room for improvement.
As suggested by clinical guidelines,9 it is critical for both patients and healthcare providers 
to initiate early and sustained management of suboptimal atherosclerotic CVD risk factors. 
As shown, the prevalence of hypercholesterolemia increased at an alarming rate in the last 
5 years. By 2018, the prevalence of dyslipidemia reached 38.4%, which is comparable to the 
prevalence in other high-income (e.g., U.S., Japan) and neighboring (e.g., China) countries.10-12 
This is unsurprising, as relevant lifestyle factors, such as physical activity and diet, have been 
worsening.13 In addition, the prevalence of dyslipidemia increased with age. This is of particular 
concern, as old age14 and longer exposure to elevated cholesterol levels15 are independently 
associated with CVD progression and treatment complications. Furthermore, the presence 
of dyslipidemia was common among people with diabetes or hypertension. The concurrent 
exposure to multiple metabolic abnormalities highlights the urgency for comprehensive 
cardiovascular health maintenance to prevent target organ damage.16
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Fig. 3. Diagnosis and treatment of dyslipidemia in Korean adults. 
(A) Changes in the estimated number of Korean adults diagnosed, treated, and adherent to treatment for 
dyslipidemia, 2002–2018. (B) Changes in the estimated number of Korean adults with dyslipidemia by lipid-
lowering drugs, 2002–2018.
Despite the high prevalence, fewer than 60% of adults with hypercholesterolemia were aware 
of their condition. This requires immediate attention. A modest treatment rate relative to 
the awareness rate and a high control rate (approximately 85%) among treated individuals 
suggest that promoting awareness may effectively improve the population-level control of 
hypercholesterolemia. Indeed, a significant proportion of atherosclerotic CVD events are 
avoidable through primordial prevention, including smoking cessation,17 regular engagement 
in physical activity,18 and adherence to a healthy diet.19 Therefore, nationwide public health 
programs should consider early diagnosis and management across the entire age spectrum 
given their acceptable cost-effectiveness and minimal moral hazard. In healthcare settings, 
practitioners should actively work with patients to evaluate their circumstances for lifestyle 
modifications, to identify potential barriers (e.g., environmental factors), to implement 
measurable goals, and to monitor progress.5
The proportion of people on dual therapy among those treated for dyslipidemia has steadily 
increased since 2015, predominantly driven by an increase of statin plus ezetimibe combination 
therapy. This coincides with findings from the IMProved Reduction of Outcomes: Vytorin 
Efficacy International Trial (IMPROVE-IT), in which the combination of a statin with ezetimibe 
improved cardiovascular outcomes compared with statin monotherapy after acute coronary 
syndrome.20 In addition, the increment in overall prescriptions of ezetimibe was almost entirely 
in the form of combination therapy, whereas ezetimibe monotherapy accounted for a negligible 
proportion. These findings are in alignment with the recent increase in combination therapy 
and expansion of reimbursement coverage for ezetimibe.
A substantial proportion (74%) of people treated for dyslipidemia received concurrent 
treatment for hypertension and/or diabetes. This proportion is expected to further increase 
with rapid population aging in Korea. Consequently, increasing healthcare expenditures will 
be inevitable. Moreover, patients will be burdened with multiple drug use, the risk of adverse 
drug reactions, or unexpected drug-drug interactions. A multidisciplinary approach may 
improve health outcomes with fewer complications among these high-risk populations.21
In conclusion, despite the established causal role of cholesterol levels in CVD progression, 
dyslipidemia continues to impose a considerable burden in Korea. In order to curb the rising 
dyslipidemia prevalence and to improve its management, monitoring trends in individual 
risk factors may provide evidence for tailored public health programs. In clinical settings, 
active communication and shared decision-making between healthcare practitioners and 
patients are essential for fulfilling the guideline recommendations. This mutual participation 
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